Key Highlights

  • Pacira agreed to divest its iovera Business to Zimmer Biomet for up to $140 million, sharpening its focus on injectable pain therapies.
  • Positive two-year Phase 1 data for gene therapy PCRX-201 in knee osteoarthritis was published in Annals of the Rheumatic Diseases in August 2026.
  • UnitedHealthcare began providing separate reimbursement for EXPAREL across outpatient settings, affecting roughly 40 million members.

Pacira BioSciences, Inc (NASDAQ: PCRX) has built its identity around non-opioid pain management, and in 2026 the company is trying to prove it can pair a stable commercial base with a genuinely novel pipeline. With its flagship product still generating the bulk of revenue, attention is increasingly turning to a gene-therapy candidate that could reshape how the market values the stock. A late-year clinical readout gives investors a concrete catalyst to anchor to.

Company and Latest Development

Headquartered in Brisbane, California, Pacira markets EXPAREL, a long-acting local anesthetic; ZILRETTA, an extended-release injection for knee osteoarthritis pain; and, until mid-2026, iovera, a handheld cryoanalgesia device. In late June 2026 the company agreed to divest the iovera business to Zimmer Biomet for up to $140 million, including $70 million upfront plus revenue-based milestones, sharpening its focus on injectable pain therapies and its pipeline. Reinforcing the commercial story, Pacira said in July that UnitedHealthcare had begun providing separate reimbursement for EXPAREL across outpatient settings, a policy shift affecting roughly 40 million members.

What Is Driving Attention Around PCRX?

The most tangible catalyst on the horizon is PCRX-201, an investigational gene therapy for knee osteoarthritis. In August 2026 Pacira announced publication of positive two-year Phase 1 data in Annals of the Rheumatic Diseases, describing the therapy as well tolerated over 104 weeks. The company has transitioned PCRX-201 to scalable commercial Manufacturing and initiated Part B enrollment in the Phase 2 ASCEND study, with top-line data expected by the end of 2026. That readout is the near-term event most likely to move sentiment, alongside the reimbursement momentum for EXPAREL.

Key Numbers and Company Position

For the second quarter of 2026, Pacira reported total Revenue of $192.4 million, up about 6% year over year, with GAAP Net Income of $4.7 million, or $0.12 per share, and non-GAAP net income of $29.5 million. By product, EXPAREL sales were $147.8 million (up 3%), ZILRETTA contributed $32.6 million (up 4%), and iovera added $6.8 million (up 22%) before the divestiture. Management guided to full-year 2026 revenue of $735 million to $760 million. The company carries a market Capitalization of roughly $1 billion, making it the largest name among comparable pain-focused peers of its size.

What Could Come Next?

The Phase 2 ASCEND top-line result for PCRX-201, expected by year-end 2026, is the marquee upcoming catalyst and could validate or challenge the gene-therapy thesis. Beyond that, investors may watch the ramp of separate EXPAREL reimbursement across additional payers, execution on the iovera divestiture, updates to full-year guidance, and the next quarterly report. Progress on scalable manufacturing for PCRX-201 also matters for any eventual commercial pathway.

Risks to Watch

EXPAREL still drives the majority of revenue, so any erosion from generic competition, Patent challenges, or shifting reimbursement policy would weigh heavily on results. The PCRX-201 program, while promising, remains early and could disappoint in the larger Phase 2 setting. Gene therapy carries manufacturing, safety and commercialization complexity. Broader pressures on elective surgical volumes and hospital budgets could also affect Demand for Pacira's injectable products.

Conclusion

Pacira BioSciences enters the final stretch of 2026 with a steady commercial engine in EXPAREL, a strengthened reimbursement backdrop, and a sharper portfolio after the iovera sale. The defining question is whether PCRX-201 can graduate from encouraging early data to convincing Phase 2 results. Investors may be watching the year-end ASCEND top-line readout, EXPAREL payer coverage trends, and full-year guidance as the developments most likely to shape the outlook for PCRX.